Navigation Links
Rigel Announces Initiation of Clinical Trials in Two Immunology Programs
Date:1/5/2012

ating other immune system disorders. Phase 1 clinical studies in normal healthy volunteers began in the fourth quarter of 2011.

R333, Topical JAK/SYK Inhibitor

Discoid Lupus Erythematosus (DLE) is an autoimmune system disorder of the skin. Inflamed disk-shaped sores on the face, chest and scalp, which may result in scaring, swelling and hair loss, characterize DLE. This disorder has an acute phase, which research has connected to SYK kinase signaling within the immune cascade. There is also a chronic phase of the disorder due to the abundance of JAK signaling. The current treatment options available for discoid lupus are few and have toxicities that further limit their use. In December 2011, Rigel began a Phase 1 clinical trial of R333, a topical JAK/SYK inhibitor, which may be useful in treating both phases of this potentially disfiguring disorder.  

R343, Inhaled SYK Inhibitor

In addition to the above clinical programs, Rigel expects to initiate a Phase 2 trial with R343, an inhaled SYK inhibitor, for patients with allergic asthma in mid-2012. This multi-center, multiple dose, placebo controlled study is expected to include approximately 300 asthma patients.  R343 will be delivered directly into the lungs via a dry inhalation device. Rigel will share additional information about its plans for R343 in future announcements.

Fostamatinib, SYK Inhibitor

In the meantime, Rigel's collaborator on fostamatinib, AstraZeneca (AZ), has indicated that the Phase 3 studies in rheumatoid arthritis are continuing as planned. The first of the OSKIRA (Oral SYK Inhibition in Rheumatoid Arthritis) studies, OSKIRA-1, completed full enrollment in the fourth quarter of 2011. OSKIRA-1 is a 12-month clinical trial of approximately 900 patients studying two dosing regimens of fostamatinib compared to placebo in patients who are not achieving an ad
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present at Oppenheimer Annual Healthcare Conference
2. Rigel Announces Third Quarter 2011 Financial Results
3. Rigel to Present at Two Upcoming Investor Conferences
4. Rigel to Present at Wells Fargo Securities Healthcare Conference
5. Rigel to Present at Jefferies Global Healthcare Conference
6. Rigel Announces Pricing of Public Offering of Common Stock
7. Rigel Announces Proposed Public Offering of Common Stock
8. Rigel to Present at Bank of America Merrill Lynch Health Care Conference
9. Rigel Announces First Quarter Financial Results
10. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
11. Rigel to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015 /CNW/ - Export Development Canada (EDC) today announced a ... Montreal,s Valeant Pharmaceuticals International, Inc. (Valeant), ... The loan is part of a ... is using to fund the repayment of certain outstanding ... pharmaceutical company based in the US. Salix was acquired ...
(Date:5/26/2015)... 26, 2015  Haemonetics Corporation (NYSE: HAE ) ... Investor Relations, will present at The East Coast IDEAS ... June 4 th , 2015 at 2:30pm Eastern time.  ... presentation live via webcast at: http://www.wsw.com/webcast/threepa16/hae ... ) is a global healthcare company dedicated to providing ...
(Date:5/26/2015)... May 26, 2015  Amgen (NASDAQ: AMGN ) ... Phase 3 OPTiM study in the Journal of ... data published in JCO , which were previously ... of Clinical Oncology (ASCO) in 2013 and 2014, demonstrated ... with unresected stage IIIB, IIIC or IV metastatic melanoma ...
Breaking Medicine Technology:EDC provides Valeant Pharmaceuticals with USD 67.5 M to support recent Salix Pharmaceuticals acquisition 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 3Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 4Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 5Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 6Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 7Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 8
... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), ... products for central nervous system disorders, today announced it will ... May 5, 2011, before the market opens. A full text ... Mihael H. Polymeropoulos, M.D., President and Chief Executive ...
... NEW BRAUNFELS, Texas, April 22, 2011 One hundred and ... challenge bike riders in the BP MS 150 overcame on ... Sclerosis. Team Freedom, a corporate team sponsored by The ... solutions and services, completed the two-day ride and raised nearly ...
Cached Medicine Technology:Vanda Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 5, 2011 2The SCOOTER Store Supports Fight Against Multiple Sclerosis 2
(Date:5/27/2015)... One of America's most cherished actors, James Earl ... that takes a look at the topic of atrial ... abnormal heart rhythm. Those who suffer from atrial fibrillation ... too quickly. , This new segment will take a ... to inform viewers about possible signs that commonly indicate ...
(Date:5/27/2015)... 27, 2015 The Academy of Oncology ... Coast Regional Meeting in Seattle. This intimate gathering, held ... 200 navigation and oncology professionals from west of the ... , “One of the most important things that an ... their needs and do the best it can to ...
(Date:5/26/2015)... 27, 2015 Carey Danis & ... testosterone gel lawsuit . The suit pertains to AndroGel, ... was filed in late April 2015, and a court ... Illinois federal court in mid-May.¹ , Testosterone gel lawsuits ... the Northern District of Illinois. The multidistrict litigation (MDL) ...
(Date:5/26/2015)... Readers who struggle with memory , ... Chester Litvin ’s new book, “ Introduction to ... Trafford Publishing). , Litvin, who is a clinical psychologist, ... This book will guide readers through a series of ... cells . He shares his patented process for reviving ...
(Date:5/26/2015)... Liverpool, Ohio (PRWEB) May 26, 2015 Mr. ... role since 2010, will start working together this week to ... an accomplished career in healthcare executive leadership and strategy. ... CEO prior to the hiring of Mr. Cochran. The Board ... skills will complement the improvement strategies implemented over the past ...
Breaking Medicine News(10 mins):Health News:AONN+’s West Coast Regional Meeting Brings Oncology Nurse and Patient Navigators Together for Two Days of Education and Networking 2Health News:AONN+’s West Coast Regional Meeting Brings Oncology Nurse and Patient Navigators Together for Two Days of Education and Networking 3Health News:Carey Danis & Lowe Comments on Recently Filed Testosterone Gel Lawsuit 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 3
... Harvard Medical School, of more than 100,000 women, indicates ... either psychiatric// illnesses or other conditions, may have an ... about 52,000 women who were taking dopamine antagonists and ... compared for breast cancer rates. It was found that ...
... of Nature Medicine by researchers in Rene Descartes University has ... vaccine which may one day let people quit their AIDS ... promising results, and if confirmed and adapted in humans may ... researchers reported that the new vaccine uses a type of ...
... age people are now increasingly taking to gardening as a ... of beautiful gardens. Though gardening has been proven to have ... gardeners who start with little or no idea of how ... up having severe back pain. ,A recent study of ...
... published in the British Medical Journal suggests that there is ... of their offspring. In contrast to overweight children given birth ... are likely to weigh less than other children. ... 186 grams less than other children and this significant difference ...
... ancient Chinese medical practices that has gained widespread ... suggest that along with other therapies, the traditional ... paediatric patients. ,A recent study which shows ... to acupuncturists, proves the popularity of the traditional ...
... Dietary Supplements & Diabetes ,A recent ... conducted by Dr.Vijay Jayagopal and his colleagues from the ... understand the benefits of dietary supplements on type 2 ... menopausal women with type 2 diabetes who //either received ...
Cached Medicine News:Health News:A Compilation of recent Diabetes Research articles 2
... the best of both worlds, the ... is the latest addition to the ... bipolar cautery instruments for ophthalmic surgery. ... extrusion aspiration and backflush functionality in ...
...
...
...
Medicine Products: